Neste generasjon av FLT3-hemmere for Akutt Myelogen Leukemi

Offentlig prosjektsammendrag

This project will enable development of a preclinical development candidate (PDC) for acute myeloid leukemia (AML) treatment, resolving the still unmet medical need of patients suffering from AML caused by FLT3 mutations (life-saving therapy). AML is the most common type of aggressive adult leukemia, and mutations in the FLT3 kinase are the most common drivers, found in 30–35% of all AML patients. FLT3 is an established AML drug target, and successful FLT3 inhibition increased survival rates in AML patients in the ADMIRAL clinical trial of the now marketed FLT3 inhibitor gilteritinib. However, marketed FLT3 inhibitors all have issues with drug induced resistance. Thus, there is an urgent need for new life-saving therapy for patients suffering from AML caused by FLT3 mutations. The project will achieve this through optimization of a compounds-series identified as potent inhibitors of FLT3 mutants.